FDA-cleared profile

Accuro 3S

Rivanna Medical, Inc. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.

Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Spine
Key limitation
Keep in mind: Since the intended use is anatomical feature tracking during scouting rather than feature segmentation accuracy for diagnostic purposes, success criteria for each anatomical annotation produced with SpineNav-AI were derived via a preliminary survey with intended users.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Spine Input: B-mode imaging from the Accuro 3S Dual-Array probe.
  • Who uses it?Intended users: Qualified and trained healthcare professionals.
  • What does the software produce?Output: The machine learning algorithm at the foundation of SpineNav-AI is a deep convolutional neural network approach to segmenting certain anatomical structures in the lumbar spine and conveying them by way of graphics to the user. A measurement to the epidural space is provided in an identical manner to SpineNav3D on the predicate Accuro (K171594) device.
  • What is its most important limitation?Key limitation: Since the intended use is anatomical feature tracking during scouting rather than feature segmentation accuracy for diagnostic purposes, success criteria for each anatomical annotation produced with SpineNav-AI were derived via a preliminary survey with intended users.

Clinical takeaway. Clinical role: Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.

Evidence takeaway. Evidence from the reviewed source record: K243937 reports software, segmentation, depth-estimation, image-quality, system, and usability validation for the lumbar-spine workflow.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
B-mode imaging from the Accuro 3S Dual-Array probe.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states B-mode imaging and the Dual-Array probe; it does not state live or imported ultrasound data as the input wording.

Output and clinician action
The machine learning algorithm at the foundation of SpineNav-AI is a deep convolutional neural network approach to segmenting certain anatomical structures in the lumbar spine and conveying them by way of graphics to the user. A measurement to the epidural space is provided in an identical manner to SpineNav3D on the predicate Accuro (K171594) device.
  • Exact FDA submission
  • Checked 2026-09-19

The packet's direct output is lumbar-spine graphics and an epidural-space measurement, not the dossier's generic calculations, overlays, and reports.

Care setting
Hospitals, clinics, offices, and point-of-care environments within the device's cleared applications.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified and trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-19

The indications statement gives this user class and does not identify the dossier's specific physician, sonographer, and other-professional list.

Limitations
Since the intended use is anatomical feature tracking during scouting rather than feature segmentation accuracy for diagnostic purposes, success criteria for each anatomical annotation produced with SpineNav-AI were derived via a preliminary survey with intended users.
  • Exact FDA submission
  • Checked 2026-09-19

This is the packet's direct scouting-versus-diagnostic boundary; the later-product-family statement in the dossier is not FDA packet text.

Evidence summary
K243937 reports software, segmentation, depth-estimation, image-quality, system, and usability validation for the lumbar-spine workflow.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243937 reports software, segmentation, depth-estimation, image-quality, system, and usability validation for the lumbar-spine workflow.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243937 FDA performance package for Accuro 3S

  • DesignManufacturer ultrasound-system, AI segmentation, measurement, and usability validation
  • PopulationLumbar spine scouting and neuraxial-procedure preparation
  • Scopeexact submission
  • Tested versionAccuro 3S release cleared in K243937
  • IndependenceSponsor or vendor study

K243937

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243937 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: B-mode imaging from the Accuro 3S Dual-Array probe.

    Scope: Exact FDA submission. The packet states B-mode imaging and the Dual-Array probe; it does not state live or imported ultrasound data as the input wording.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K243937: Accuro 3S

  2. Routing

    Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K243937: Accuro 3S · RIVANNA Accuro 3S

  3. AI processing

    Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K243937: Accuro 3S · RIVANNA Accuro 3S

  4. Returned objects

    Source context, not route validation: The machine learning algorithm at the foundation of SpineNav-AI is a deep convolutional neural network approach to segmenting certain anatomical structures in the lumbar spine and conveying them by way of graphics to the user. A measurement to the epidural space is provided in an identical manner to SpineNav3D on the predicate Accuro (K171594) device.

    Scope: Exact FDA submission. The packet's direct output is lumbar-spine graphics and an epidural-space measurement, not the dossier's generic calculations, overlays, and reports.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K243937: Accuro 3S

  5. Viewer/worklist/report

    Unresolved route: The machine learning algorithm at the foundation of SpineNav-AI is a deep convolutional neural network approach to segmenting certain anatomical structures in the lumbar spine and conveying them by way of graphics to the user. A measurement to the epidural space is provided in an identical manner to SpineNav3D on the predicate Accuro (K171594) device.

    Scope: Exact FDA submission. The packet's direct output is lumbar-spine graphics and an epidural-space measurement, not the dossier's generic calculations, overlays, and reports.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K243937: Accuro 3S

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified physicians, sonographers, and other trained ultrasound professionals. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: K243937 supports the cleared scouting and measurement workflow. Later product-family claims about real-time in-plane guidance are not attributed to this release without exact clearance evidence.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K243937 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. K243937 supports the cleared scouting and measurement workflow. Later product-family claims about real-time in-plane guidance are not attributed to this release without exact clearance evidence.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: K243937 supports the cleared scouting and measurement workflow. Later product-family claims about real-time in-plane guidance are not attributed to this release without exact clearance evidence.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243937
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA K243937: Accuro 3S

    U.S. Food and Drug Administration - Published 2025-05-23 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RIVANNA Accuro 3S

    RIVANNA Medical - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

Research history

  1. K243937 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241029

SpineUs™ System

Verdure Imaging

Authorized purpose: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.

Modality
Ultrasound
Anatomy
Spine
Decision
2024-10-07
FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260190

ARTHUR

ROPCA ApS

Authorized purpose: Supervised automatic ultrasound image acquisition of hand and wrist joints in adults being investigated or monitored for musculoskeletal disease.

Modality
Ultrasound
Anatomy
Hand/Wrist
Decision
2026-06-18
FDA-cleared K260844

ACUSON Sequoia Diagnostic Ultrasound System;ACUSON Sequoia Select Diagnostic Ultrasound System;ACUSON Origin Diagnostic Ultrasound System;ACUSON Origin ICE Diagnostic Ultrasound System

Siemens Medical Solutions USA, Inc.

Authorized purpose: ACUSON Sequoia, Select, Origin, and Origin ICE diagnostic ultrasound systems acquire and display the labeled fetal, abdominal, pediatric, neonatal, cephalic, small-part, obstetric, cardiac, transesophageal, intracardiac, vascular, and musculoskeletal examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; transesophageal and intracardiac applications
Decision
2026-06-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history